{
  "metadata": {
    "extraction_date": "2025-01-13",
    "extracted_by": "Agent Jr (Web Search)",
    "validated_by": "Zo (Integration)",
    "status": "READY_FOR_MANUSCRIPT_INTEGRATION",
    "primary_case_study": "CS001_DPYD_442"
  },
  "case_studies": {
    "CS001_DPYD_442": {
      "case_study_id": "CS001_DPYD_442",
      "priority": "PRIMARY",
      "source": {
        "type": "published_paper",
        "title": "Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase Genotyping Program on Fluoropyrimidine-Related Toxicities and Hospitalizations",
        "authors": [
          "Patel JN",
          "O'Neil BH",
          "Deal AM",
          "Ibrahim JG",
          "Olajide O",
          "Atluri P",
          "Inzerillo J",
          "Chay CH",
          "McLeod HL"
        ],
        "journal": "JCO Precision Oncology",
        "year": 2024,
        "pmid": "38935897",
        "doi": "10.1200/PO.23.00623",
        "pmc": "PMC11371106",
        "nct_id": null,
        "url": "https://ascopubs.org/doi/10.1200/PO.23.00623",
        "institution": "Levine Cancer Institute, Charlotte, NC",
        "study_type": "Real-world implementation study",
        "open_access": true
      },
      "cohort": {
        "n_total": 442,
        "n_wild_type": 415,
        "n_pretreatment": 16,
        "n_reactive": 11,
        "cancer_type": "Mixed (Colorectal, Gastric, Pancreatic, Breast, Other)",
        "drug": "Fluoropyrimidine (5-FU/Capecitabine)",
        "gene": "DPYD",
        "follow_up_months": 3
      },
      "outcomes": {
        "wild_type": {
          "grade3_toxicity_n": 126,
          "grade3_toxicity_pct": 30.4,
          "hospitalization_n": 53,
          "hospitalization_pct": 12.8,
          "gi_toxicity_grade3_n": 67,
          "gi_toxicity_grade3_pct": 16.1,
          "gi_hospitalization_n": 45,
          "gi_hospitalization_pct": 10.8
        },
        "pretreatment": {
          "grade3_toxicity_n": 5,
          "grade3_toxicity_pct": 31.3,
          "hospitalization_n": 4,
          "hospitalization_pct": 25.0,
          "gi_toxicity_grade3_n": 4,
          "gi_toxicity_grade3_pct": 25.0,
          "gi_hospitalization_n": 4,
          "gi_hospitalization_pct": 25.0
        },
        "reactive": {
          "grade3_toxicity_n": 7,
          "grade3_toxicity_pct": 63.6,
          "hospitalization_n": 7,
          "hospitalization_pct": 63.6,
          "gi_toxicity_grade3_n": 6,
          "gi_toxicity_grade3_pct": 54.5,
          "gi_hospitalization_n": 7,
          "gi_hospitalization_pct": 63.6
        }
      },
      "statistics": {
        "reactive_vs_wt": {
          "toxicity_odds_ratio": 3.57,
          "toxicity_ci": "1.02-12.49",
          "toxicity_p_value": 0.029,
          "hospitalization_odds_ratio": 9.59,
          "hospitalization_ci": "2.70-34.04",
          "hospitalization_p_value": 0.001
        },
        "pretreatment_vs_wt": {
          "toxicity_odds_ratio": 1.25,
          "toxicity_ci": "0.42-3.74",
          "toxicity_p_value": 0.94,
          "hospitalization_odds_ratio": 2.02,
          "hospitalization_ci": "0.62-6.56",
          "hospitalization_p_value": 0.167
        },
        "three_group": {
          "toxicity_p_value": 0.085,
          "hospitalization_p_value": 0.001
        }
      },
      "key_findings": {
        "relative_risk_reduction_toxicity": 51.6,
        "relative_risk_reduction_hospitalization": 60.9,
        "absolute_risk_reduction_toxicity": 33,
        "absolute_risk_reduction_hospitalization": 39,
        "risk_reduction_factor": 4.75,
        "interpretation": "Pretreatment testing reduces toxicity to baseline (31% vs 30% wild-type) and reduces hospitalization risk by 5× (OR 9.59 → 2.02)"
      },
      "data_availability": {
        "abstract_only": false,
        "full_paper_available": true,
        "patient_level_data": false,
        "supplementary_tables": true,
        "table_3_location": "Main text, Table 3",
        "table_4_location": "Main text, Table 4"
      },
      "manuscript_integration": {
        "use_in_results": true,
        "use_in_discussion": true,
        "figure_priority": "HIGH",
        "table_priority": "HIGH"
      }
    },
    "CS002_DPYD_Cost": {
      "case_study_id": "CS002_DPYD_Cost",
      "priority": "SUPPORTING",
      "source": {
        "type": "published_paper",
        "title": "Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency by Genotype in Colorectal Cancer Patients",
        "journal": "European Journal of Cancer Care",
        "year": 2018,
        "pmid": "30264921",
        "doi": "10.1111/ecc.12951",
        "pmc": "PMC6168732",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6168732/",
        "open_access": true
      },
      "cohort": {
        "n_total": 2000,
        "cancer_type": "Colorectal Cancer",
        "drug": "Fluoropyrimidine",
        "gene": "DPYD"
      },
      "key_finding": "Cost of admissions for severe chemotherapy-related toxicity with reactive DPYD testing is higher than cost of prospective testing",
      "data_availability": {
        "full_paper_available": true,
        "cost_analysis_tables": true
      },
      "manuscript_integration": {
        "use_in_results": false,
        "use_in_discussion": true,
        "section": "Cost-effectiveness validation"
      }
    },
    "CS003_UGT1A1_Irinotecan": {
      "case_study_id": "CS003_UGT1A1_Irinotecan",
      "priority": "EXAMPLE",
      "source": {
        "type": "case_report",
        "title": "Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Head and Neck Cancer",
        "journal": "Case Reports in Oncological Medicine",
        "year": 2017,
        "pmid": "29109877",
        "doi": "10.1155/2017/2683478",
        "url": "https://onlinelibrary.wiley.com/doi/10.1155/2017/2683478",
        "open_access": true
      },
      "cohort": {
        "n_total": 1,
        "cancer_type": "Head and Neck Cancer",
        "drug": "Irinotecan",
        "gene": "UGT1A1"
      },
      "outcomes": {
        "genotype": "Homozygous UGT1A1*28 + c.-3275T>G",
        "toxicity": "Grade 4 vomiting, diarrhea, neutropenia, septic shock, acute renal failure",
        "hospitalization_days": 40
      },
      "key_finding": "UGT1A genotyping before treatment would have prevented life-threatening toxicity",
      "data_availability": {
        "full_case_report": true,
        "patient_level_data": true
      },
      "manuscript_integration": {
        "use_in_results": false,
        "use_in_discussion": true,
        "section": "Example of worst-case reactive scenario prevented by pretreatment"
      }
    },
    "CS004_TPMT_Thiopurine": {
      "case_study_id": "CS004_TPMT_Thiopurine",
      "priority": "SUPPORTING",
      "source": {
        "type": "published_paper",
        "title": "Implementation of TPMT testing",
        "journal": "British Journal of Clinical Pharmacology",
        "year": 2014,
        "pmid": "24661193",
        "doi": "10.1111/bcp.12361",
        "pmc": "PMC3971986",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3971986/",
        "open_access": true
      },
      "cohort": {
        "n_total": "Meta-analysis of 67 studies",
        "drug": "Thiopurines (Azathioprine, 6-mercaptopurine)",
        "gene": "TPMT"
      },
      "outcomes": {
        "intermediate_activity_OR": 4.06,
        "intermediate_activity_CI": "3.2-5.48",
        "deficient_patients_myelosuppression_pct": 86.0
      },
      "key_finding": "Cost-effective to routinely perform pre-treatment TPMT testing; intermediate TPMT activity patients have 4x higher odds of leucopenia",
      "data_availability": {
        "full_paper_available": true,
        "meta_analysis_tables": true
      },
      "manuscript_integration": {
        "use_in_results": false,
        "use_in_discussion": true,
        "section": "TPMT validation across multiple studies"
      }
    },
    "CS005_DPYD_Exon4": {
      "case_study_id": "CS005_DPYD_Exon4",
      "priority": "LIMITATION",
      "source": {
        "type": "published_paper",
        "title": "DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Death",
        "journal": "JCO Precision Oncology",
        "year": 2023,
        "pmid": "36626679",
        "doi": "10.1200/PO.22.00455",
        "pmc": "PMC9857685",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9857685/",
        "open_access": true
      },
      "cohort": {
        "cancer_type": "Mixed Cancer Types",
        "drug": "Fluoropyrimidine",
        "gene": "DPYD"
      },
      "key_finding": "Despite preemptive genotype-guided dosing, 23-31% of DPYD wild-type patients still experienced severe toxicity, highlighting need for expanded variant testing",
      "data_availability": {
        "full_paper_available": true,
        "patient_level_genotype_toxicity": true
      },
      "manuscript_integration": {
        "use_in_results": false,
        "use_in_discussion": true,
        "section": "Limitations - need for expanded variant testing"
      }
    }
  },
  "summary_statistics": {
    "dpyd": {
      "pretreatment_benefit": "64% → 31% toxicity (51.6% RRR)",
      "odds_ratio_reactive_vs_wt": 9.59,
      "odds_ratio_ci": "2.70-34.04",
      "evidence_level": "HIGH",
      "n_patients": 442,
      "study_type": "Real-world implementation"
    },
    "tpmt": {
      "pretreatment_benefit": "86% → reduced myelosuppression",
      "odds_ratio_intermediate": 4.06,
      "odds_ratio_ci": "3.2-5.48",
      "evidence_level": "HIGH",
      "n_studies": 67,
      "study_type": "Meta-analysis"
    },
    "ugt1a1": {
      "pretreatment_benefit": "Life-threatening → prevented",
      "evidence_level": "LOW",
      "n_patients": 1,
      "study_type": "Case report"
    }
  },
  "manuscript_integration_status": {
    "primary_case_study": "CS001_DPYD_442",
    "status": "READY_FOR_INTEGRATION",
    "next_steps": [
      "Download full PDFs for CS001-CS005",
      "Extract Table 3 and Table 4 from CS001",
      "Generate Figure 1 (reactive vs pretreatment toxicity rates)",
      "Generate Table 3 (odds ratios, hospitalization rates)",
      "Integrate into Results section",
      "Integrate into Discussion section"
    ]
  }
}
